Holly C. Rickman

Array ( [id] => 17356809 [patent_doc_number] => 20220017605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => HUMAN ANTIBODIES TARGETING ZIKA VIRUS NS1, NS1 POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/289448 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299865 [patent_doc_number] => 20210395704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => NANOBODY-GLYCAN MODIFYING ENZYME FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/289613 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30084 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482200 [patent_doc_number] => 20220089704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => HUMANIZED AND STABILIZED FC5 VARIANTS FOR ENHANCEMENT OF BLOOD BRAIN BARRIER TRANSPORT [patent_app_type] => utility [patent_app_number] => 17/288445 [patent_app_country] => US [patent_app_date] => 2019-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336098 [patent_doc_number] => 20220002429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => TUMOR CELL AGGREGATION INHIBITORS' FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/309115 [patent_app_country] => US [patent_app_date] => 2019-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200145 [patent_doc_number] => 20210340240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => COMBINATION OF A BIG-H3 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF SOLID TUMOR [patent_app_type] => utility [patent_app_number] => 17/283607 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19778559 [patent_doc_number] => 12227583 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use [patent_app_type] => utility [patent_app_number] => 17/278259 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 16396 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214548 [patent_doc_number] => 20210347885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => SYNTHETIC BINDING AGENTS FOR LIMITING PERMEATION THROUGH MUCUS [patent_app_type] => utility [patent_app_number] => 17/278217 [patent_app_country] => US [patent_app_date] => 2019-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18340436 [patent_doc_number] => 20230132385 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-04-27 [patent_title] => ANTIBODIES SPECIFIC TO CTLA-4 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/278261 [patent_app_country] => US [patent_app_date] => 2019-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18340436 [patent_doc_number] => 20230132385 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-04-27 [patent_title] => ANTIBODIES SPECIFIC TO CTLA-4 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/278261 [patent_app_country] => US [patent_app_date] => 2019-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411779 [patent_doc_number] => 12077586 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Bispecific antibodies for use in the treatment of hematological malignancies [patent_app_type] => utility [patent_app_number] => 17/277984 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 12 [patent_no_of_words] => 16656 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657122 [patent_doc_number] => 20220177587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => METHODS AND USES OF VARIANT CD80 FUSION PROTEINS AND RELATED CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 17/275646 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17532434 [patent_doc_number] => 20220111043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => DUAL ACTING CD1D IMMUNOGLOBULIN [patent_app_type] => utility [patent_app_number] => 17/277906 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19701534 [patent_doc_number] => 12195543 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Anti-FLT [patent_app_type] => utility [patent_app_number] => 17/275647 [patent_app_country] => US [patent_app_date] => 2019-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 28279 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156138 [patent_doc_number] => 20210317189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => FORMULATIONS OF IMMUNOGLOBULIN A [patent_app_type] => utility [patent_app_number] => 17/273784 [patent_app_country] => US [patent_app_date] => 2019-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16357 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17273784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16961619 [patent_doc_number] => 20210213118 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => ANTIBODIES SPECIFIC FOR NTSR1 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/250734 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29287 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17250734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19550949 [patent_doc_number] => 12134645 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-05 [patent_title] => Monoclonal antibodies against human tim-3 [patent_app_type] => utility [patent_app_number] => 17/270405 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8586 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17270405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19473892 [patent_doc_number] => 12103968 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => Antibodies to human ZnT8 [patent_app_type] => utility [patent_app_number] => 17/268925 [patent_app_country] => US [patent_app_date] => 2019-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 22 [patent_no_of_words] => 22462 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17268925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533680 [patent_doc_number] => 20220112289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS [patent_app_type] => utility [patent_app_number] => 17/264507 [patent_app_country] => US [patent_app_date] => 2019-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17264507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17096941 [patent_doc_number] => 20210284732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => DOSING REGIMEN FOR BCMA-CD3 BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/264386 [patent_app_country] => US [patent_app_date] => 2019-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31585 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17264386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214544 [patent_doc_number] => 20210347881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => INHIBITION OF KIDNEY DISEASE RELAPSE BY TARGETED CYTOKINE DEPLETION [patent_app_type] => utility [patent_app_number] => 17/262625 [patent_app_country] => US [patent_app_date] => 2019-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17262625 [rel_patent_id] =>[rel_patent_doc_number] =>)